The hallmarks of aging · Where the damage starts

Protein misfolding

Scientific name: Loss of proteostasis

Proteins do most of the work in a cell, and each one has to fold into the right shape. Cells have systems that fold proteins, repair them, and break down damaged ones. With age these systems slip, and misfolded proteins build up and clump together.

Measurable today: no routine test. A few disease tests read specific clumping proteins.

Why it matters

Why it matters to you

Clumped proteins harm cells.

Misfolded proteins can stick together and jam the cell's machinery. Cells that rarely or never divide, like nerve and heart muscle cells, cannot dilute the clumps, so they are hit hardest.

It sits under several diseases of aging.

Protein clumps are central to Alzheimer's and Parkinson's disease and to a form of heart failure caused by a misfolded blood protein, transthyretin. In a large trial, a drug that holds that protein in shape lowered deaths and hospital stays from this condition.

Source: PubMed 30145929

The upkeep systems weaken with age.

The cell's protein recycling machinery and the stress response that makes repair proteins both lose capacity over the years, leaving older cells less able to handle extra strain.

Measurement

Can it be measured?

Brain-protein tests for Alzheimer's (amyloid and tau)

Doctor-ordered tests

What it showsWhether two specific proteins linked to Alzheimer's disease are building up in the brain, from spinal fluid, brain scans, or newer blood tests.

LimitsThey are disease tests for one condition. They do not measure protein upkeep across the body or how fast you are aging.

Damaged-protein and stress-protein markers in blood

Some specialty labs

What it showsLevels of chemically damaged (oxidized) proteins, or of stress proteins that cells release under strain.

LimitsThere are no standard ranges. Stress proteins in blood can also reflect inflammation, so a result is hard to interpret.

Protein-recycling and tissue lab methods

Research only

What it showsHow well cells break down proteins, and how much clumped or damaged protein a tissue holds, from biopsies or isolated cells.

LimitsThese need tissue or cell samples and specialized labs, with no normal ranges for one person.

What would make it measurable

  • A blood test that reflects protein upkeep across the body, not one disease.
  • Agreed methods to measure protein recycling in a simple sample.
  • Proof that improving these measures means healthier aging.
What can be done

What can be done about it?

Three items in our catalog have human studies that support an effect on protein upkeep. Products in this space mostly claim to boost the cell's cleanup systems. No product has been shown to clear protein clumps in healthy people or to slow aging this way.

Three examples from our catalog, rotated daily: one with stronger evidence here, one with early evidence, and one where we found none. A sample, not a ranking or a recommendation. Ratings as of October 25, 2026. What the evidence levels mean.

Botanical

Green Tea Extract (EGCG-standardized)

Evidence for protein misfolding: Supported

Human studies support it engaging this aging driver, short of the strongest trial designs.

Vitamins & Minerals

Vitamin K2 (MK-4)

Evidence for protein misfolding: Emerging

Only early or animal-stage evidence for this aging driver so far.

Metabolites & Cofactors

Phosphatidylcholine

Evidence for protein misfolding: None found

We did not find qualifying evidence that it engages this aging driver.

Its stronger evidence is for disrupted cell signaling.

See the full picture for your own routine

The Longevity Intelligence Report shows how what you take and do covers protein misfolding and the other hallmarks. Members also see every item in our catalog ranked by the strength of its evidence for protein misfolding. Opens in December.

Get early access
New research

New studies on protein misfolding

Picked for what they add to the biology, and to the chance of one day treating it, in plain words. Research checked October 17, 2026.

Protein misfolding

When a protein-cleanup system fails with age, senescent cells linger

Mice and cells · Nature Aging · October 5, 2026

What they foundA selective protein-cleanup system declines with age. Cells lacking it became senescent cells that were harder for immune cells to clear. A drug that switched the system back on reduced senescent cells in old mice.

What it does not showMice and cells only, and the activating drug is experimental. It does not show the same works in people.

Why it mattersIt links two aging drivers: failing protein upkeep helps senescent cells pile up, and that link can be targeted.

Read the study on PubMed ↗
Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.
Protein misfolding

Signs of failing protein upkeep appeared from age 40 in human nose-lining cells

People, 213 healthy volunteers aged 2 to 97, plus donor lung tissue · Aging Cell · May 1, 2026

What they foundIn cells brushed from the nose lining, telomere damage showed up almost only after age 80. Signs of failing protein upkeep appeared from about age 40 and tracked a decline in the sense of smell.

What it does not showA snapshot across ages, not people followed over time, and the markers used are indirect.

Why it mattersIn this human tissue, protein upkeep, not telomeres, looked like the earlier driver of cell aging.

Read the study on PubMed ↗
Telomere Dysfunction and Proteostasis Decline Define Distinct Pathways of Cellular Senescence in the Human Respiratory Tract.
Protein misfolding

Oxidative damage switched off brain protein-recycling enzymes in old animals, reversibly

Mice and killifish, plus neurons grown from human stem cells · Nature Communications · April 21, 2026

What they foundIn aging mouse and fish brains, enzymes that help route proteins to recycling lost activity even though their amount stayed the same. Oxidative damage was the cause, and an antioxidant compound restored their activity. The loss came before the recycling machine itself declined.

What it does not showAnimals and lab cells only. It does not show the antioxidant protects memory or slows brain aging.

Why it mattersIt points to an early, possibly reversible step in how the aging brain loses protein upkeep.

Read the study on PubMed ↗
Oxidative stress causes a reversible decrease of deubiquitylases activity in old vertebrate brains.

Follow the research on protein misfolding

Pick the ones you want to follow. Starting in December, we'll email you every two weeks when new studies or new tests come out on them. Longevity Intelligence Report members also get the plain-English read on each one: why it matters, and whether it should change what you're doing.

Free, no account needed. We keep your email and the topics you pick, nothing else. Unsubscribe anytime.

From the articles

Articles on protein misfolding

Go deeper

Connected hallmarks

How the biology works

Folding is the whole game, and it fails more often with age. A protein is made as a plain chain of building blocks (amino acids) that then has to fold itself into one exact shape to function, like a strip of paper that only works once folded into a specific origami figure. Heat, oxidative stress (chemical wear from reactive oxygen species, the unstable oxygen byproducts of normal metabolism), and simple copying errors during protein-making all push proteins to misfold. A misfolded protein is not just useless; its sticky inner surfaces, normally tucked away, get exposed, so misfolded copies tend to glue to one another and to other proteins.

Molecular chaperones are the folding helpers and first responders. Chaperones are a class of proteins whose job is to help other proteins fold correctly and to grab ones that have slipped out of shape. The best-known are the heat-shock proteins (named because the cell makes more of them under heat and other stress), including HSP70 and HSP90. A chaperone either coaxes a damaged protein back into its correct fold or, if it is too far gone, escorts it to one of the disposal crews. With age the cell's chaperone supply and the stress response that ramps it up both weaken, so more misfolded proteins slip through.

The unfolded protein response is the cell's alarm for a folding backlog. A large share of proteins are folded inside the endoplasmic reticulum (the ER), a folding-and-packaging factory inside the cell. When misfolded proteins start to pile up there faster than they can be cleared, the ER triggers a coordinated alarm called the unfolded protein response (UPR), run by three sensor proteins named PERK, IRE1, and ATF6. The UPR briefly slows down new protein-making to ease the backlog and orders up more chaperones to clear it. If the overload is resolved, the cell recovers; if it drags on unresolved, the same alarm flips toward driving inflammation and ordering the cell to self-destruct.

The ubiquitin-proteasome system is the shredder for single damaged proteins. When a protein is beyond repair, the cell flags it for destruction by clipping on a chain of a small marker protein called ubiquitin, which works like a disposal tag. The tagged protein is then fed into the proteasome, a barrel-shaped shredder that chops it back down into reusable building blocks. This system handles most short-lived and damaged individual proteins, and its capacity falls with age, so tagged junk clears more slowly.

Chaperone-mediated autophagy is a second, selective disposal route, and it belongs to this hallmark. In chaperone-mediated autophagy (CMA), a chaperone called HSC70 recognizes a specific tag sequence on a worn-out protein, carries it one at a time to the lysosome (the cell's acidic recycling compartment), and feeds it through a dedicated gate protein in the lysosome wall called LAMP-2A. Because CMA picks off individual proteins, it sits inside the proteostasis hallmark. This is the key boundary to keep straight: CMA is part of protein misfolding, while bulk macroautophagy, the separate process that wraps up large clumps and whole worn-out structures for recycling, is its own distinct hallmark, autophagy decline. protein misfolding is about handling individual proteins and small cargo; the large-scale bulk cleanup lives in autophagy decline.

When clearance loses the race, proteins aggregate, and that is the damaging endpoint. If folding helpers and disposal crews cannot keep up, misfolded proteins stick together into insoluble clumps called aggregates. Several specific aggregates define major diseases: amyloid-beta plaques and tangles of a protein called tau in Alzheimer's disease, and clumps of a protein called alpha-synuclein in Parkinson's disease. These aggregates are both a consequence of failing proteostasis and a fresh source of stress, because they tie up chaperones and clog the disposal machinery, which makes the whole system fall further behind.

Where treatment research is heading
Next few years

Heat-shock-response and chaperone-inducing approaches available today

Heat exposure such as sauna use, and to a lesser degree exercise, reliably switch on the cell's own heat-shock response, prompting it to make more of its folding-helper chaperones. This is a low-risk lever people can use now, and the population data on regular sauna use are at least consistent with a brain and cardiovascular benefit.

Not ready yet: The chain from more chaperones to actually preventing human protein-aggregation disease is associative, not proven by intervention trials, and the sauna evidence comes from observational populations where other healthy habits are hard to separate out.

Aggregate-imaging biomarkers as a window into proteostasis failure

Amyloid and tau PET brain scans, and blood markers of neuronal damage such as neurofilament light chain, now let researchers and clinicians see aggregate buildup and its downstream nerve injury years before symptoms, turning a once-invisible process into something trackable.

Not ready yet: These read out disease-specific aggregates in the brain, not whole-body protein-quality-control capacity, they are costly or confined to specialist settings, and a scan showing aggregate load does not yet come with a proven way to clear it.

Further out

Proteasome activators and chemical chaperones to boost clearance and folding

Compounds that rev up the proteasome shredder, and chemical chaperones such as 4-phenylbutyrate and trehalose that help stabilize folding or stimulate clearance, can improve protein handling in cell and animal models, aiming to restore capacity the aging cell has lost.

Not ready yet: Human dosing, getting these molecules into the brain where they are most needed, and any disease-modifying benefit remain unestablished, and broadly cranking up degradation risks chewing through healthy proteins too.

Targeted protein degraders and aggregate-clearance therapeutics for specific diseases

A new class of designer molecules, including targeted protein degraders (often called PROTACs) that drag a chosen damaged protein to the cell's shredder, plus antibody therapies aimed at specific aggregates, could remove toxic proteins that older drugs cannot touch. Antibodies against amyloid in Alzheimer's are the first members of this idea to reach the clinic.

Not ready yet: The first approved amyloid antibodies remove plaque but deliver only modest clinical slowing and carry real brain-swelling and bleeding risks, the diffuse aggregates of aging are hard to target selectively, and the safety of broad protein degradation in healthy tissue is unknown.

Long shots

Engineered proteostasis networks and broad chaperone-capacity restoration

The far-horizon vision is to rebuild the cell's entire quality-control network, safely and durably topping up chaperone supply, proteasome capacity, and the UPR's responsiveness across whole tissues, so the cell keeps clearing damaged proteins at a youthful pace instead of slowly falling behind. Long-lived species appear to invest more heavily in exactly this kind of protein maintenance.

Not ready yet: We do not yet know the right youthful settings for each tissue, how to deliver and dose such a system-wide reset safely across the body, or how to avoid the cancer and toxicity risks of pushing these tightly regulated pathways too hard, so this remains a distant, high-risk goal.

Facts and sources on this page checked October 17, 2026. This page explains research. It is not medical advice or a recommendation to take anything. How we grade the evidence.